Staging preview: health content pending qualified review
D2C Peptides

Dosage information

Sermorelin dosage

No current human dose of sermorelin is established: its only approvals, a treatment for GH-deficient children and a one-time diagnostic test, were withdrawn in 2009.12 This page records the doses used in published human studies, with population, route and length. They are research history, not guidance for anyone.

This page summarizes published sources for information only. It is not medical advice and does not tell anyone to use a product. Questions about your own health belong with a licensed clinician. For questions about an order or a product, contact us.

No established human dose

FDA approved sermorelin (Geref) for only two uses: treating idiopathic GH deficiency in children with growth failure, and testing the pituitary's ability to secrete growth hormone.1 Both approvals were withdrawn effective June 18, 2009.1 Drugs@FDA offers no Geref label, and DailyMed returns no sermorelin labels, so there is no label dosing table to reproduce.910 A 2026 review notes that no current approval covers body-composition or performance use.2

No dose is established for adults.12 The doses below come from small, mostly short studies. They show what researchers gave to specific groups, and they are not guidance for anyone. For how dose units and study doses are read in general, see Peptide dosage basics. The compound itself is described in What is Sermorelin?

Doses used in published studies

All studies below were in humans. Doses written in mcg/kg scale with body weight; doses in mg were fixed amounts.

Study Who Dose and route Length
Geref International Study Group, multicenter open-label 110 prepubertal GH-deficient children 30 mcg/kg once daily under the skin at bedtime3 Up to 1 year3
Drug review, diagnostic use Children tested for GH deficiency One IV dose of 1 mcg/kg, alongside conventional GH tests4 Single test
Randomized trial (Chen) 40 children with GH deficiency of hypothalamic origin (20 more were given GH) 30 or 60 mcg/kg per day by continuous infusion7 6 months7
Randomized trial (Neyzi) 27 of 43 prepubertal children aged 4.3 to 18.9 (the other 16 were given GH) 30 or 60 mcg/kg per day under the skin, split into three doses11 6 months11
Pharmacokinetic study (Wilton) 30 healthy men aged 19 to 43 1 to 2 mcg/kg IV gave maximal GH release; about 50 mcg/kg in the nose matched 1 mcg/kg IV8 Single doses, plus one day of three nasal doses8
Randomized dose order (Corpas) 10 nonobese older men, plus 9 young men for comparison 0.5 mg or 1 mg under the skin twice daily5 14 days per dose5
Before-and-after study (Vittone) 11 healthy men aged 64 to 76 with low IGF-1 2 mg under the skin nightly, self-injected at home6 6 weeks6
Chart review (Sigalos) 14 men on testosterone therapy 100 mcg each of sermorelin, GHRP-2 and GHRP-6 under the skin, three times daily; sermorelin never given alone12 Mean 134 days13
Intranasal pilot (Hummelink) 8 short prepubertal children 50 mcg/kg sprayed into the nose three times daily14 6 months14
Related analog, not sermorelin (Khorram) 10 women and 9 men aged 55 to 71 10 mcg/kg of [Nle27]GHRH(1-29)-NH2 under the skin nightly15 16 weeks after 4 weeks of placebo15

What the dose studies showed

  • Dose size mattered in older men. Only the 1 mg twice-daily dose significantly raised 24-hour GH and IGF-1; the 0.5 mg dose did not reach significance.5
  • Once-nightly dosing looked weaker. A single nightly 2 mg dose raised nighttime GH but not IGF-1, and the authors suggested single nightly doses are less effective than multiple daily doses.6
  • In one child trial, the higher daily dose did better. In the Neyzi trial, where both doses were split into three injections, 60 mcg/kg per day gave growth comparable to GH, while 30 mcg/kg per day gave the lowest growth.11
  • Continuous infusion fell short of GH. The Chen authors concluded that continuous GHRH infusion is unlikely to be as effective as GH for growth.7
  • The nasal route absorbed poorly. In healthy men, only 3 to 5% of a nasal dose reached the blood; in children the spray's effect faded, and the authors ruled the form unsuitable.814

These results describe study groups, measured with study methods. They do not convert into an amount for any person.

Routes and timing in the studies

Studies gave sermorelin under the skin, into a vein, by continuous infusion or as a nasal spray.4714 The peptide clears from the blood within minutes, with a disappearance half-time near 4.3 minutes according to a 2026 review.2 Even so, GH stayed raised for about 3 hours after one IV dose.8 Nasal absorption was only 3 to 5%, and about 50 mcg/kg in the nose gave the GH response of 1 mcg/kg into a vein.8

What the studies measured

Endpoints differed by group. Child trials measured height velocity over 6 to 12 months.37 Adult studies measured GH and IGF-1, and the 6-week study added strength tests and DEXA body composition.56 A 1999 review noted that the effect on final adult height had not been determined.4 No study here followed long-term outcomes, and no long-term safety data exist.2

Why study doses do not transfer

Study groups were selected. The children were GH-deficient, the 6-week study enrolled older men with low IGF-1, and the 14-day study enrolled nonobese men.365 Other factors changed the response in testing. In a GH test of 14 obese and 9 normal-weight women, the obese group peaked at a mean 8.9 mU/L against 28 mU/L, and in another study atropine cut the GH response.1617 So a dose used in one group cannot be assumed to apply to another.

How online regimens compare with study doses

A 2026 review set dosing regimens from fitness and bodybuilding websites beside the regimens used in peer-reviewed studies to show how widely they vary.2 The review adds that in unregulated supply chains, product content, dosing and stacking are all uncertain.18 Labeled strength is not always what a vial holds: compounded sermorelin has been recalled as out of specification, and the recall notice, posted by FDA, warns that such products can lead to too much or too little being given.19

Reported effects and warnings: Sermorelin side effects. What the studies found, with evidence levels: Sermorelin benefits and uses. Lab handling and concentration math for the vial: How to reconstitute Sermorelin. Unit arithmetic only: Peptide units converter. The 10 mg research vial is described at Sermorelin for sale.

More on Sermorelin

  • Sermorelin side effects

    Side effects of Sermorelin as reported in clinical trials and published studies, with links to the full profile. Reviewed by a qualified reviewer.

  • Sermorelin benefits and uses

    What published sources report about Sermorelin and its uses, with the evidence level of each finding. No promises.

  • How to reconstitute Sermorelin

    How Sermorelin is reconstituted, the supplies used, and the calculator, step by step. Sourced and reviewed.

Sermorelin in the store

Sermorelin for sale: strengths, stock and shipping are on the product page.

For research use only. Not for human or veterinary use. Read the research use policy.

Frequently asked questions

Is there a standard sermorelin dosage?

No. No dose is established for any person, and this page does not give one. Sermorelin's only FDA approvals, a treatment for children with GH deficiency and a one-time diagnostic test, were withdrawn in 2009.1 What exists is study history: the doses researchers gave to specific groups, listed in the table on this page with population, route and length. A 2026 review set regimens from fitness websites beside study regimens to show how widely they vary.2

Do you have to cycle off sermorelin?

Published studies did not test cycling schedules, so the sources reviewed here cannot answer this. The longest data come from children. During 6 months of GHRH(1-29)-NH2, IGF-1 rose at first and then fell back to about pretreatment values.7 Nearly all of those children formed GHRH antibodies, which had almost disappeared 9 months after treatment stopped.7

Is 3 months of Sermorelin enough?

No study reviewed here sets a course length for adults. Adult studies of sermorelin alone were short: 14 days at each of two doses in 10 older men, and 6 weeks of nightly injections in 11 older men.56 In GH-deficient children treated for 6 months, IGF-1 rose at first and then returned to about pretreatment values.7 Three months is longer than any adult study of sermorelin alone.

How long does it take for sermorelin to start working?

It depends on what is measured. After a single IV dose in healthy men, GH stayed raised for about 3 hours.8 In older men, 14 days on the higher tested dose raised GH and IGF-1, while 6 weeks of single nightly doses raised nighttime GH but not IGF-1.56 In GH-deficient children, faster growth was measured at 6 months.3

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (78 FR 14095, Docket FDA-2012-P-1071). U.S. Food and Drug Administration, Federal Register (GovInfo), 2013.
  2. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Dominikowski et al.), evidence tier. Front Endocrinol (PMC full text PMC13322892), 2026.
  3. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group (Thorner et al.). J Clin Endocrinol Metab (PubMed abstract PMID 8772599, via NCBI E-utilities), 1996.
  4. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency (Prakash and Goa), conclusion. BioDrugs (PubMed abstract PMID 18031173, via NCBI E-utilities), 1999.
  5. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men (Corpas et al.), design. J Clin Endocrinol Metab (PubMed abstract PMID 1379256, via NCBI E-utilities), 1992.
  6. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men (Vittone et al.), design. Metabolism (PubMed abstract PMID 9005976, via NCBI E-utilities), 1997.
  7. A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency (Chen et al.), design. Acta Paediatr Suppl (PubMed abstract PMID 8329830, via NCBI E-utilities), 1993.
  8. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration (Wilton et al.), intranasal. Acta Paediatr Suppl (PubMed abstract PMID 8329825, via NCBI E-utilities), 1993.
  9. Drugs@FDA: GEREF, NDA 020443. U.S. Food and Drug Administration, 2026.
  10. DailyMed search results for sermorelin. U.S. National Library of Medicine (DailyMed), 2026.
  11. Same source as 7: Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone (Neyzi et al.), design and growth.
  12. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels (Sigalos et al.), full text. Am J Mens Health (PMC full text PMC5675260), 2017.
  13. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels (Sigalos et al.), results. Am J Mens Health (PubMed abstract PMID 28830317, via NCBI E-utilities), 2017.
  14. Same source as 8: Intranasal administration of growth hormone-releasing hormone(1-29)-NH2 in children with growth hormone deficiency (Hummelink et al.), dose and growth.
  15. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women (Khorram et al.), design. J Clin Endocrinol Metab (PubMed abstract PMID 9141536, via NCBI E-utilities), 1997.
  16. Impaired growth hormone response to growth hormone releasing factor and insulin-hypoglycaemia in obesity (Kopelman et al.). Clin Endocrinol (Oxf) (PubMed abstract PMID 2863016, via NCBI E-utilities), 1985.
  17. Influence of dopaminergic, adrenergic and cholinergic blockade and TRH administration on GH responses to GRF 1-29 (Jordan et al.). Clin Endocrinol (Oxf) (PubMed abstract PMID 2871952, via NCBI E-utilities), 1986.
  18. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis (Dominikowski et al.), abstract: supply chains. Front Endocrinol (PubMed abstract PMID 42395176, via NCBI E-utilities), 2026.
  19. Olympia Pharmacy Issues Voluntary Nationwide Recall of Seven Compounded Products Due to Being Out-of-Specification (company announcement posted by FDA, March 10, 2022). U.S. Food and Drug Administration, 2022.